Brighter carries out a directed share issue of SEK 5 M.

Cision |

Brighter's Board of Directors has, with authorization from the Annual General Meeting on , decided on a directed issue. The share issue totalling SEK 5 million will be made through cash payment and the cash amount received will then be fully utilized to repay loans from these lenders. The purpose of the share issue and the reason for the deviation from the shareholders' preferential rights is to strengthen the company's balance sheet in a time and capital efficient manner.


10% discount on the closing share price on . The subscription price is SEK 9,63 kr.

The number of shares in the company increases by 520,000, to a total of 85,556,043. The share capital increases by SEK 26,000 to SEK 4,277,802,15

About Brighter AB (publ).

Brighter is a Swedish-based company that, from a unique IP portfolio, creates smart solutions for one of healthcare's biggest challenges: changing patient behavior. Chronic diseases such as diabetes are rapidly increasing, and account for an increasing share of healthcare costs globally. Brighter's Business Model and Multi-Sided Market Platform - The Benefit Loop®- is based on the fact that many special interests create value for each other. By increasing access to valid health data, Brighter creates value for all stakeholders in the care chain: patients and their close associates, healthcare providers, research institutes, the pharmaceutical industry, and society as a whole. Brighter is certified under ISO 13485. In 2019 the company won the Swecare Rising Stars Award.  

The Company's shares are listed on NASDAQOMX First North/BRIG (

Visit our website and subscribe to press releases: (

Follow us on:  (

Certified Adviser

Brighter's Certified Adviser on Nasdaq OMX First North is Eminova Fondkommission AB, +46 (0)8 - 684 211 00,,

For further information, please contact:

Henrik Norström, CEO  Phone: +46 733 40
30 45    Email:

This information is information that Brighter AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at on .,c2862370

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to:



Symbol Last Price Change % Change






INTERVIEW: CEO Steve Stanulis - Stanulis Films's Sam Mitchell interviewing CEO Steve Stanulis of Stanulis Films.